ACTG2 is altered in 0.08% of all cancers with lung adenocarcinoma, acute myeloid leukemia, cancer of unknown primary, diffuse large B-cell lymphoma, not otherwise specified, and glioblastoma having the greatest prevalence of alterations .
The most common alteration in ACTG2 is ACTG2-ALK Fusion (0.08%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.